Lantheus (NASDAQ:LNTH) updated its FY 2019 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.14-1.17 for the period, compared to the Thomson Reuters consensus estimate of $0.96. The company issued revenue guidance of $357.967-363.118 million, compared to the consensus revenue estimate of $361.49 million.Lantheus also updated its Q1 2019 guidance to $0.23-0.25 EPS.
Several equities research analysts have issued reports on the company. BidaskClub raised Lantheus from a hold rating to a buy rating in a research note on Thursday, November 22nd. Zacks Investment Research raised Lantheus from a hold rating to a buy rating and set a $19.00 target price for the company in a research note on Tuesday, February 5th. Finally, ValuEngine cut Lantheus from a buy rating to a hold rating in a research note on Wednesday, January 2nd. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Lantheus currently has a consensus rating of Hold and an average target price of $20.33.
NASDAQ:LNTH traded up $0.62 during midday trading on Tuesday, reaching $19.16. The company had a trading volume of 326,216 shares, compared to its average volume of 160,033. The firm has a market cap of $713.14 million, a PE ratio of 19.16, a price-to-earnings-growth ratio of 3.56 and a beta of 1.47. Lantheus has a 12-month low of $12.59 and a 12-month high of $21.45. The company has a current ratio of 3.50, a quick ratio of 2.87 and a debt-to-equity ratio of 4.76.
In other Lantheus news, CEO Mary Anne Heino sold 9,564 shares of Lantheus stock in a transaction dated Wednesday, January 30th. The stock was sold at an average price of $16.47, for a total transaction of $157,519.08. Following the completion of the sale, the chief executive officer now directly owns 630,782 shares of the company’s stock, valued at approximately $10,388,979.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Cesare Orlandi sold 4,057 shares of Lantheus stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $18.06, for a total value of $73,269.42. Following the sale, the insider now directly owns 73,689 shares of the company’s stock, valued at $1,330,823.34. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,736 shares of company stock valued at $408,523. 1.20% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://macondaily.com/2019/02/19/lantheus-lnth-releases-fy-2019-earnings-guidance.html.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.